Key Findings
Enhertu® (trastuzumab deruxtecan), the HER2-targeted antibody-drug conjugate (ADC) jointly developed and commercialized by Daiichi Sankyo and AstraZeneca, has received approval in China for the adjuvant treatment of HER2-positive early breast cancer. This approval specifically targets adult patients who have residual invasive disease after completing neoadjuvant taxane and trastuzumab-based therapy. The decision is based on groundbreaking results from the Phase 3 DESTINY-Breast05 trial, which showed Enhertu reduced the risk of invasive disease recurrence or death by a remarkable 53% compared to trastuzumab emtansine (T-DM1), potentially establishing a new standard of care in China.
Technical / Clinical Details
Enhertu is a sophisticated ADC composed of a humanized anti-HER2 monoclonal antibody covalently linked to a topoisomerase I inhibitor payload, deruxtecan, via a stable tetrapeptide-based cleavable linker. This design ensures targeted delivery of the cytotoxic agent to HER2-expressing cancer cells, where the payload is released intracellularly, leading to potent anti-tumor activity. The DESTINY-Breast05 study was an international, open-label, randomized Phase 3 trial evaluating the efficacy and safety of Enhertu versus T-DM1 in patients with HER2-positive early breast cancer who had residual invasive disease after neoadjuvant chemotherapy. The primary endpoint, invasive disease-free survival (iDFS), demonstrated a statistically significant and clinically meaningful improvement with Enhertu, achieving a Hazard Ratio of 0.47 (95% CI: 0.37-0.60; p < 0.000001). This translated to a 53% reduction in the risk of invasive disease recurrence or death. The safety profile was manageable and generally consistent with the known safety profile of Enhertu.
- Targeted Delivery: The trastuzumab component precisely binds to HER2 receptors, enabling selective delivery of the potent cytotoxic payload to HER2-overexpressing cancer cells.
- Potent Payload: Deruxtecan, a topoisomerase I inhibitor, induces DNA damage and apoptosis in cancer cells.
- Bystander Effect: The cleavable linker allows for the release of the payload in the tumor microenvironment, leading to a ‘bystander effect’ that can target adjacent tumor cells, even those with low HER2 expression, enhancing overall efficacy.
- Patient Population: The approval addresses a high-risk population in early breast cancer, where residual disease after neoadjuvant therapy carries a poor prognosis and a high unmet need for more effective adjuvant treatments.
Background & Context
Breast cancer is the most common cancer among women in China, with HER2-positive breast cancer being an aggressive subtype associated with rapid progression and higher recurrence rates. Patients who have residual disease after neoadjuvant therapy are known to have a worse prognosis, underscoring the critical need for more effective post-operative adjuvant treatments. While Enhertu has already demonstrated significant efficacy in the metastatic setting for HER2-positive breast cancer, its approval in the earlier adjuvant setting represents a paradigm shift. This earlier intervention aims to prevent recurrence and improve long-term survival outcomes. The superior efficacy demonstrated over T-DM1, a previous standard in this setting, highlights the advancement of ADC technology and the continued progress in precision oncology.
Strategic Significance & Outlook
The approval of Enhertu in China for HER2-positive early breast cancer in the adjuvant setting is a landmark achievement, promising to significantly improve outcomes for a large patient population. This expands Enhertu’s market reach and reinforces its position as a leading ADC in oncology. For the broader pharmaceutical industry, it underscores the strategic importance of ADCs as a modality capable of transforming treatment paradigms across various stages of cancer. Researchers, engineers, and investors will continue to monitor the impact of this approval, as it not only enhances the prognosis for Chinese breast cancer patients but also provides strong validation for further ADC development in similar high-need indications globally.
Source: https://www.daiichisankyo.com/files/news/pressrelease/pdf/202610/20261008_E3.pdf
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
